Acorda Therapeutics, Inc. announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld all four patents challenged via the inter partes review (IPR) process. U.S. Patent Nos. 8,663,685 (the ‘685 patent), 8,440,703 (the ‘703 patent), 8,354,437 (the ‘437 patent) and 8,007,826 (the ‘826 patent) apply to Ampyra (dalfampridine) Extended Release Tablets, 10 mg. The patents are set to expire in 2025, 2025, 2026 and 2027, respectively.

“The court decision reflects the merits of the case we presented and the validity and strength of our intellectual property for Ampyra,” said Ron Cohen, M.D., Acorda’s President and CEO. “Medical innovation depends on the recognition of valid intellectual property claims. Our in-house legal team and external counsel presented a compelling case, and will continue to defend the validity of our intellectual property rights for Ampyra.”

Acorda was advised by Gerald Flattmann, Naveen Modi, Thomas Phalen, Michael Stamiello, Daniel Zeilberger, and Lucas Kressel of Paul Hastings LLP.

The patents, as well as U.S. Patent No. 5,540,938 that also pertains to Ampyra, have also been challenged in the U.S. District Court for the District of Delaware. The court has completed the trial of the case, but not yet issued its decision.

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. Acorda markets three FDA-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 mg.

(Source: Business Wire)